ERBB2 and neoplasm: Successful approaches are represented by treatment with humanized ERBB2-targeting antibodies (e.g., trastuzumab and pertuzumab) and tyrosine kinase multi-HER inhibitors (e.g., lapatinib, tucatinib, afatinib, neratinib, and dacomitinib), which effectively showed ERBB2 inhibition and tumor regression, particularly in the treatment of mammary carcinomas [reviewed in (109)].